Limits...
Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.

Zhang ZY, Li C, Zug C, Schluesener HJ - PLoS ONE (2014)

Bottom Line: Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities.Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment.Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany.

ABSTRACT
Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Show MeSH

Related in: MedlinePlus

Therapeutic effect of Icariin on microglial and astrocytic activation.A and B: Representative microimages with higher magnification show the changes in microglial activation in cortex following Icariin treatment. C and D: Representative microimages show typical morphology of astrocytes, including stellate shape and multiple branched processes. No massive aggregation of GFAP+ cells and no obvious changes of GFAP IR were observed.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4125230&req=5

pone-0104616-g005: Therapeutic effect of Icariin on microglial and astrocytic activation.A and B: Representative microimages with higher magnification show the changes in microglial activation in cortex following Icariin treatment. C and D: Representative microimages show typical morphology of astrocytes, including stellate shape and multiple branched processes. No massive aggregation of GFAP+ cells and no obvious changes of GFAP IR were observed.

Mentions: In both cortex and hippocampus of non-transgenic mice, Iba-1 staining could be barely observed. In transgenic mice, however, amoeboid Iba1+ microglia were observed clustered around amyloid deposits in both control and treatment groups (Figure 3C and G, Figure 5A with higher magnification), according to comparison with Aβ staining of serial sections. Numbers of Iba-1+ cells in Icariin treatment group were significantly less than those of the control group. Notably, in the cortex; decreased Iba-1+ cells were also less clustered around plaques (Figure 3D and H, Figure 5B with higher magnification). Further analysis showed that Icariin treatment significantly reduced the IR area of Iba-1 in cortex (control = 0.35±0.06%, Icariin = 0.21±0.04%, p<0.05, n = 6), and hippocampus (control = 0.29±0.03%, Icariin = 0.16±0.05%, p<0.05, n = 6) (Figure 4E and F). These results indicate reduced microglial activation.


Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.

Zhang ZY, Li C, Zug C, Schluesener HJ - PLoS ONE (2014)

Therapeutic effect of Icariin on microglial and astrocytic activation.A and B: Representative microimages with higher magnification show the changes in microglial activation in cortex following Icariin treatment. C and D: Representative microimages show typical morphology of astrocytes, including stellate shape and multiple branched processes. No massive aggregation of GFAP+ cells and no obvious changes of GFAP IR were observed.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4125230&req=5

pone-0104616-g005: Therapeutic effect of Icariin on microglial and astrocytic activation.A and B: Representative microimages with higher magnification show the changes in microglial activation in cortex following Icariin treatment. C and D: Representative microimages show typical morphology of astrocytes, including stellate shape and multiple branched processes. No massive aggregation of GFAP+ cells and no obvious changes of GFAP IR were observed.
Mentions: In both cortex and hippocampus of non-transgenic mice, Iba-1 staining could be barely observed. In transgenic mice, however, amoeboid Iba1+ microglia were observed clustered around amyloid deposits in both control and treatment groups (Figure 3C and G, Figure 5A with higher magnification), according to comparison with Aβ staining of serial sections. Numbers of Iba-1+ cells in Icariin treatment group were significantly less than those of the control group. Notably, in the cortex; decreased Iba-1+ cells were also less clustered around plaques (Figure 3D and H, Figure 5B with higher magnification). Further analysis showed that Icariin treatment significantly reduced the IR area of Iba-1 in cortex (control = 0.35±0.06%, Icariin = 0.21±0.04%, p<0.05, n = 6), and hippocampus (control = 0.29±0.03%, Icariin = 0.16±0.05%, p<0.05, n = 6) (Figure 4E and F). These results indicate reduced microglial activation.

Bottom Line: Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities.Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment.Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany.

ABSTRACT
Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Show MeSH
Related in: MedlinePlus